MODERNA INC

Moderna’s share plunge after its melanoma vaccine trial shows how even positive oncology results can miss investor hype, underscoring the volatility of biotech stocks.

Moderna’s stock climbs 34% amid a sharp EPS drop, as Phase‑3 cancer therapy data fuels investor intrigue and modest revenue upside.

Moderna shares jump 6.69%, hitting a 24‑hour high of $242.08 as investors back its mRNA innovation and AI‑driven biopharma strategy.